A5000688965- Neuroendocrine Tumor Research Advances
- Metabolism, Diabetes, and Cancer
- Colorectal Cancer Treatments and Studies
- Growth Hormone and Insulin-like Growth Factors
- Cancer Treatment and Pharmacology
- Adipokines, Inflammation, and Metabolic Diseases
- Venous Thromboembolism Diagnosis and Management
- Economic and Financial Impacts of Cancer
- MicroRNA in disease regulation
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Lipids, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Mechanisms and Therapy
- HER2/EGFR in Cancer Research
- Cancer-related gene regulation
- Multiple and Secondary Primary Cancers
- Lung Cancer Treatments and Mutations
- Inflammatory Biomarkers in Disease Prognosis
- Acute Myocardial Infarction Research
- Gastric Cancer Management and Outcomes
- Cardiac Imaging and Diagnostics
Medical University of Silesia
2019-2025
Wojewódzki Szpital Specjalistyczny nr 4 w Bytomiu
2019-2025
Background: Pulmonary embolism (PE) is the third most common cause of death for cardiovascular diseases in Europe. Quick PE diagnosis therefore crucial prognosis improvement. It critical to have suitable screening tests both exclude as well select patient with highest likelihood occurrence. Currently D-dimer test accepted important tool useful low risk patients. Our goal was assess positive prognostic value. Methods: A retrospective study based on medical record analysis consecutively...
Chronic inflammation is a confirmed risk factor for colorectal cancer (CRC). Indicators of systemic inflammatory response (SIR), such as neutrophil-to-lymphocyte ratio (NLR) or platelet-to-lymphocyte (PLR), are easily accessible indicators the generalized response. At molecular level, inflammation-related carcinogenesis involves proteins from adamalysin family: ADAM10 and ADAM17. The aim study was to assess NLR PLR their relationship with selected clinical parameters in CRC patients, well...
This was an observational study prospectively evaluating the effectiveness and safety of aflibercept/FOLFIRI administered in second-line mCRC per reimbursement criteria Poland. Consecutive patients who progressed with first-line oxaliplatin-based chemotherapy received aflibercept (4 mg/kg IV) followed by FOLFIRI every 2 weeks until progression or unacceptable toxicity. The primary endpoint progression-free survival (PFS); overall (OS) were secondary endpoints. A total 93 treated at 17 Polish...
Abstrakt Nowotwory złośliwe przewodu pokarmowego zajmują czołowe miejsce zarówno wśród przyczyn zachorowań jak i zgonów z powodu chorób nowotworowych na świecie. Wciąż poszukuje się potencjalnych biomarkerów, które mogłyby posłużyć jako czynniki predykcyjne prognostyczne w tych nowotworach. Wśród białek, pełnić taką rolę, wymienia adamalizyny. Liczne białka tej rodziny są zaangażowane wielu etapach nowotworzenia, od procesu różnicowania pojedynczych komórek, wzrost progresję guza do...